Venus Remedies,  a research based pharmaceutical company, has bagged additional patent for Vancoplus from USPTO. Vancoplus is an antibiotic adjuvant entity effective in one the most deadly resistance by methicillin resistance Staphylococcus Aureus (MRSA).

Developed by the Venus Medicine Research Centre (VMRC), the R&D wing of Venus Remedies, Vancoplus is the only solution till date for MRSA with more than 9% of success rate.

The patent is valid till 2032. The company has already initiated process for pre IND meeting with USFDA and is quite optimistic to get fast track approval for this product because MRSA is under the list of limited pathogens indentified under GAIN act by FDA and Vancoplus falls in that QIDP category.

Shares of the company declined Rs 2.55, or 0.84%, to trade at Rs 299.45. The total volume of shares traded was 49,539 at the BSE (1.28 p.m., Monday).